Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Wall Street estimates and companywide momentum will be tested when CVS Health reports second-quarter results, as attention centers on Aetna-driven efforts and performance across its major operations.
THE APEX TIMES
THE APEX TIMES
The FDA’s Breakthrough Therapy designation can accelerate development and review for medicines intended for serious conditions where preliminary clinical evidence suggests substantial improvement.
THE APEX TIMES
The pharmaceutical company is set to report quarterly results Tuesday before markets open, according to a market preview from Yahoo Finance.
THE APEX TIMES
A market comparison published Tuesday framed Abbott Laboratories as cheaper on valuation while highlighting Eli Lilly’s faster top-line growth and an expanded profit margin, elevating the stakes for companies seeking defensible earnings growth in healthcare.
THE APEX TIMES
In its latest update, Moderna said early results from an interim Phase 3 analysis for its lead norovirus vaccine candidate did not meet predefined success criteria, meaning the study will continue while regulators weigh its next steps for MFLUSIVA.
THE APEX TIMES
A new market headline argues Eli Lilly could reach a $2 trillion market value within five years, potentially becoming the first major healthcare company to do so.
THE APEX TIMES
After several Street updates, analysts are again marking up Johnson & Johnson’s outlook, pointing to a higher “fair value” range and suggesting the company’s execution is holding up better than some investors expected.
THE APEX TIMES
A Yahoo Finance market note points to a shift in Pfizer’s (PFE) valuation picture, arguing the stock’s longer-term underperformance is no longer paired with the same degree of perceived “cheap” or “expensive” pricing.
THE APEX TIMES
A fresh wave of earnings-related talk and continued attention to store growth are bringing CVS Health back into investor spotlights, with the shares trading around the mid-$100s and the debate centered on how much good news is already priced in.
